(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)
By Jason Napodano, CFA
Last night, Cytomedix, Inc. (OTCQX:CMXI) announced it would restructure its R&D activities in the coming months to reduce cash burn and focus on profitability. This is the second major business reorganization in as many months for the company. Last month, the company announced it had signed a commercial partnership for its Angel, whole blood Concentrated PRP System. Both moves are designed to move the company toward profitability as it prepares to dramatically ramp-up operations around AutoloGel, the company's point-of-care autologous PRP wound care product.
The primary focus of yesterday's announced reorganization will...
Only subscribers can access this article, which is part of the PRO research library covering 3,559 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: